AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
carbachol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 488 | 51-83-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 6 | mg | O |
| 0.50 | mg | P |
| 0.40 | ml | None |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPK9,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 50 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,EPHB4,FLT3,GRK2,MAP3K21,MAP3K9,MAPK7,SIK2,STK33,TEK,TTK | 17 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 28, 1972 | FDA | ALCON |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07AB01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Choline esters |
| ATC | S01EB02 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:38147 | cardiotonic drug |
| CHEBI has role | CHEBI:38325 | muscarinic agonist |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:47958 | nicotinic acetylcholine receptor agonist |
| CHEBI has role | CHEBI:51068 | miotic |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D002316 | Cardiotonic Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D008916 | Miotics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D020011 | Protective Agents |
Related Drugs by ATC class:
N07AB Choline esters 1 drug
S01EB Parasympathomimetics 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
| Secondary glaucoma | off-label use | 95717004 | |
| Angle-closure glaucoma | off-label use | 392291006 | DOID:13550 |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Abdominal pain | contraindication | 21522001 | |
| Parkinsonism | contraindication | 32798002 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Low blood pressure | contraindication | 45007003 | |
| Bradycardia | contraindication | 48867003 | |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Asthma | contraindication | 195967001 | DOID:2841 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 8455494 | May 24, 2030 | TREATMENT OF PRESBYOPIA |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 8455494 | May 24, 2030 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF BRIMONIDINE AND CARBACHOL ONCE DAILY |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 8455494 | May 24, 2030 | USE OF YUVEZZI FOR THE TREATMENT OF PRESBYOPIA IN ADULTS |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 12268662 | Nov. 10, 2042 | TREATMENT OF PRESBYOPIA |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 12268662 | Nov. 10, 2042 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF BRIMONIDINE AND CARBACHOL ONCE DAILY |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 12268662 | Nov. 10, 2042 | USE OF YUVEZZI FOR THE TREATMENT OF PRESBYOPIA IN ADULTS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | Jan. 28, 2029 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | EC50 | 8.70 | WOMBAT-PK | CHEMBL | |||
| Muscarinic acetylcholine receptor M2 | GPCR | EC50 | 7.92 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | EC50 | 7.58 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | EC50 | 8.10 | WOMBAT-PK | |||||
| Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 4.18 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 6.12 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | EC50 | 8.52 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.40 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.51 | CHEMBL | |||||
| Acetylcholine receptor subunit delta | Ion channel | Ki | 6.35 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 8.10 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.70 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.10 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.59 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Kd | 4.74 | CHEMBL | |||||
| Acetylcholine receptor subunit alpha | Ion channel | IC50 | 5.12 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 6.68 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 5.96 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 5.32 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 6.23 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 5.89 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Ki | 8.89 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018583 | VUID |
| N0000146899 | NUI |
| D00524 | KEGG_DRUG |
| 1999 | RXNORM |
| C0006945 | UMLSCUI |
| CHEBI:3385 | CHEBI |
| CHEMBL14 | ChEMBL_ID |
| D002217 | MESH_DESCRIPTOR_UI |
| 5831 | PUBCHEM_CID |
| 383 | INN_ID |
| 298 | IUPHAR_LIGAND_ID |
| 8Y164V895Y | UNII |
| 1101 | MMSL |
| 1253 | MMSL |
| 177672 | MMSL |
| 4349 | MMSL |
| 4801 | MMSL |
| 33675006 | SNOMEDCT_US |
| 387183001 | SNOMEDCT_US |
| CCE | PDB_CHEM_ID |
| DB00411 | DRUGBANK_ID |
| 4018583 | VANDF |
| 001690 | NDDF |
| 8Y164V895Y | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| MIOSTAT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0023 | SOLUTION | 0.10 mg | OPHTHALMIC | NDA | 15 sections |
| YUVEZZI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 84892-275 | SOLUTION/ DROPS | 27.50 mg | OPHTHALMIC | NDA | 27 sections |